Quantum BioPharma Statistics
Total Valuation
QNTM has a market cap or net worth of $27.08 million. The enterprise value is $24.79 million.
Important Dates
The last earnings date was Thursday, March 26, 2026, after market close.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QNTM has 3.83 million shares outstanding. The number of shares has increased by 189.02% in one year.
| Current Share Class | 5.72M |
| Shares Outstanding | 3.83M |
| Shares Change (YoY) | +189.02% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 8.92% |
| Float | 5.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.31 |
| P/TBV Ratio | 11.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.07 |
| Quick Ratio | 0.43 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.74 |
Financial Efficiency
Return on equity (ROE) is -346.87% and return on invested capital (ROIC) is -104.85%.
| Return on Equity (ROE) | -346.87% |
| Return on Assets (ROA) | -67.64% |
| Return on Invested Capital (ROIC) | -104.85% |
| Return on Capital Employed (ROCE) | -299.89% |
| Weighted Average Cost of Capital (WACC) | 8.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.54M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.37% in the last 52 weeks. The beta is 0.60, so QNTM's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -31.37% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 12.66 |
| Relative Strength Index (RSI) | 61.86 |
| Average Volume (20 Days) | 576,960 |
Short Selling Information
The latest short interest is 229,208, so 5.98% of the outstanding shares have been sold short.
| Short Interest | 229,208 |
| Short Previous Month | 83,550 |
| Short % of Shares Out | 5.98% |
| Short % of Float | 4.46% |
| Short Ratio (days to cover) | 0.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.30M |
| Pretax Income | -26.96M |
| Net Income | -26.18M |
| EBITDA | -14.76M |
| EBIT | -15.30M |
| Earnings Per Share (EPS) | -$8.20 |
Full Income StatementBalance Sheet
The company has $2.36 million in cash and $1.88 million in debt, with a net cash position of $488,226 or $0.13 per share.
| Cash & Cash Equivalents | 2.36M |
| Total Debt | 1.88M |
| Net Cash | 488,226 |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 5.10M |
| Book Value Per Share | 1.81 |
| Working Capital | 420,059 |
Full Balance SheetCash Flow
| Operating Cash Flow | -8.24M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 545,780 |
| Net Borrowing | 3.75M |
| Free Cash Flow | -8.24M |
| FCF Per Share | -$2.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
